Plans to evaluate the safety through clinical trials on patients with knee osteoarthritis
LG Chem announced on Nov. 4 that it has received approval from the Korean Ministry of Food and Drug Safety for the Phase 1b/2 clinical trials based on the positive pre-clinical results of LG00034053, a new drug candidate for treatment of osteoarthritis.
LG Chem plans to accelerate the development of new drugs by designing clinical trials which links Phases 1 and 2.
Through this approval, LG Chem will conduct research at Samsung Medical Center to evaluate indicators such as safety and tolerability, pharmacokinetics, and effectiveness in patients with mild and moderate knee osteoarthritis, to select the most optimal dose.
President Son Jee-wong of the Life Sciences Co., stated “For all the arthritis patients around the world who still suffer from limited treatment options, we will develop a new drug that not only relieves the pain but also prevents the progression and the cause of the disease.”